Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Genmab

1.321

 

DKK

 

+2,01 %

Mindre end 1K følgere

GMAB

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Investor consensus
Sammenligne
+2,01%
+2,17%
-12,17%
-11,49%
-8,9%
-36,03%
-35,02%
-32,46%
+3.773,9%

Genmab er et farmaceutisk selskab. Virksomheden har specialiseret sig i forskning og udvikling af antistoffer, som hovedsageligt bruges til behandling af kræftpatienter med lymfatisk leukæmi og solide tumorer. Forskning og udvikling er baseret på virksomhedens egen udviklede tekniske platform, og driften foregår på globalt plan. Genmab blev grundlagt i 1999 og har sit hovedkontor med beliggenhed i København.

Læs mere
Markedsværdi
84,7 mia. DKK
Aktieomsætning
278,06 mio. DKK
Omsætning
21,53 mia.
EBIT %
31,14 %
P/E
10,81
Udbytteafkast, %
-
Finanskalender
7.8
2025

Delårsrapport Q2'25

6.11
2025

Delårsrapport Q3'25

Alle
Analyse
Selskabsmeddelelser
ViserAlle indholdstyper
Pressemeddelelse14.5.2025, 14.15

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress

Genmab
Selskabsmeddelelse12.5.2025, 12.50

Transactions in Connection with Share Buy-back Program

Genmab
Selskabsmeddelelse8.5.2025, 15.01

Genmab Announces Financial Results for the First Quarter of 2024

Genmab

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Selskabsmeddelelse5.5.2025, 12.23

Transactions in Connection with Share Buy-back Program

Genmab
Selskabsmeddelelse2.5.2025, 00.14

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab
Selskabsmeddelelse28.4.2025, 12.16

Transactions in Connection with Share Buy-back Program

Genmab
Selskabsmeddelelse22.4.2025, 11.23

Transactions in Connection with Share Buy-back Program

Genmab
Selskabsmeddelelse15.4.2025, 10.21

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Genmab
Selskabsmeddelelse14.4.2025, 12.42

Transactions in Connection with Share Buy-back Program

Genmab
Selskabsmeddelelse10.4.2025, 16.20

Genmab A/S Share Capital Reduction

Genmab
Selskabsmeddelelse7.4.2025, 11.42

Transactions In Connection with Share Buy-back Program

Genmab
Selskabsmeddelelse1.4.2025, 19.53

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Genmab
Pressemeddelelse31.3.2025, 15.20

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

Genmab
Selskabsmeddelelse31.3.2025, 12.18

Transactions in connection with share buy-back program

Genmab
Pressemeddelelse27.3.2025, 12.00

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

Genmab
Selskabsmeddelelse25.3.2025, 21.28

Genmab Announces Initiation of Share Buy-Back Program

Genmab
Selskabsmeddelelse22.3.2025, 03.28

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

Genmab
Pressemeddelelse17.3.2025, 16.19

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Genmab
Selskabsmeddelelse12.3.2025, 18.19

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Genmab
Selskabsmeddelelse12.3.2025, 18.13

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Genmab
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.